Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
Systematic review	People with psoriasis (severity not reported), number of people in analysis not reported	Local adverse effects with vitamin D derivatives with placebo	ARR 0% 95% CI –2% to +2%		Not significant
RCT 3-armed trial	1136 people with moderate or severe psoriasis	Skin problems (mainly itch, worsening psoriasis, and skin irritation) 15% with calcipotriene 11% with placebo Absolute numbers not reported	Significance not assessed
RCT 3-armed trial	1136 people with moderate or severe psoriasis	Adverse effects at 8 weeks 40% with calcipotriene 37% with placebo Absolute numbers not reported	OR 1.17 95% CI 0.87 to 1.56 P = 0.31		Not significant
RCT	97 people with psoriasis that was stable for at least 3 months, and who had finished at least 6 months' treatment with methotrexate	Adverse effect 77% with maintenance treatment with calcipotriol 78% with placebo Absolute numbers not reported	P = 0.009		Not significant
RCT 5-armed trial	144 people with bilateral plaque psoriasis involving less than 20% of the body surface	Withdrawal owing to adverse effects 12/144 (8%) with maxacalcitol at any dose not reported with placebo Absolute results reported graphically